Abraxis BioScience, Inc.
11755 Wilshire Boulevard
20th Floor
Los Angeles,
CA 90025
Phone: 310-883-1300
Fax: 310-998-8553
Web Site: http://www.abraxisbio.com
| Abraxis BioScience, Inc., a biotechnology company, engages in the discovery, development, and delivery of next-generation therapeutics and core technologies that offer treatments for cancer and other critical illnesses. The companys product pipeline includes clinical oncology and cardiovascular product candidates in various stages of testing and development. Its principal product includes Abraxane, a nanoparticle chemotherapeutic compound that is based on its proprietary tumor targeting nab technology platform for the treatment of metastatic breast cancer. Abraxis BioSciences other clinical product candidates include ABI-008, a solvent-free, Tween-free nanometer-sized form of docetaxel for the treatment of hormone refractory prostate cancer and metastatic breast cancer; ABI-009, a nab-rapamycin mTOR inhibitor for the treatment of solid tumors; ABI-010, a polyketide inhibitor of heat shock protein 90 for the treatment of multiple cancers; ABI-011, a thiocolchicine dimer for microtubule destabilization and the disruption of topoisomerase-1 activity; and Coroxane, a nanometer-sized paclitaxel for coronary restenosis and peripheral artery restenosis. It has strategic relationships with Taiho Pharmaceutical Co., Ltd.; Biocon Limited; and ProMetic Life Sciences Inc. Abraxis BioScience also has licensing agreements with Green Cross Corporation and University of Southern California. The company was formerly known as New Abraxis, Inc. and changed its name to Abraxis Bioscience, Inc. in November 2007. Abraxis BioScience is based in Los Angeles, California. |
|
| Key Statistics |
|
|
|
| |
Pay |
Exercised |
Dr. Patrick Soon-Shiong M.D., 58
Chairman, Exec. Chairman of Abraxis Health and Chief Exec. Officer of Abraxis Health
|
$
1.51M |
$
0 |
Mr. Bruce Wendel J.D., 54
Chief Exec. Officer, Vice Chairman, Exec. VP of Corp. Operations & Devel., Vice Chairman of Abraxis Health and Exec. VP of Global Bus. Devel. - Abraxis Health
|
$
547.00K |
$
0 |
Mr. Richard Rodgers , 43
Chief Financial Officer and Sr. VP
|
N/A
|
N/A |
Dr. Mary Lynne Hedley Ph.D., 47
Chief Scientific Officer and Exec. VP of Operations
|
N/A
|
N/A |
Mr. Carlo Montagner BSc, MSc, Grad Dip Child Psychology, 43
Pres of Abraxis Oncology Pan Asia
|
N/A
|
N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
|
|
|
Help
Profile
